CSF
VictoryShares US Discovery Enhanced Volatility Wtd ETF
Set alert
51.03 USD +0.14 +0.28%
51.00 Day range 51.39
46.65 52-week range 60.63
- YTD
- -7.02%
- 1 year
- +3.34%
- Open
- 51.34
- Prev close
- 50.89
- Mkt cap
- 30.72M
- Vol
- 17.10K
- Avg vol
- 2.19K
- EPS
- 0.00
- P/E
- 16.42
- Div yield
- 0.00%
More statistics
- Low
- 51.00
- High
- 51.39
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 56.81
- 200-d avg
- 52.70
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 16.42
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 56.81
- 200-day average
- 52.70
About VictoryShares US Discovery Enhanced Volatility Wtd ETF
The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory U.S. Small Cap 500 Long/Cash Volatility Weighted Index. The index identifies the 500 largest U.S. companies with market capitalizations of less than $3 billion measured at the time the index's constituent securities are determined.
News
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease
- Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
- Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
- Cerenome Launches CNSide® CSF Molecular Profile Tests
- New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
- Chime Scholars Foundation Announces 2026–2027 Cohort
- Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
- Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
Your note
Sign in to keep a note on CSF — it syncs with the Stock Master app.